

Evidence of a causal effect of genetic tendency to gain muscle mass on uterine leiomyomata

Received: 19 November 2021

Accepted: 10 January 2023

Published online: 01 February 2023

 Check for updates

Eeva Sliz^{1,2} ✉, Jaakko S. Tyrmi^{1,2}, Nilufer Rahmioglu^{3,4}, Krina T. Zondervan^{3,4}, Christian M. Becker³, FinnGen^{*}, Outi Uimari^{5,6,7,72} & Johannes Kettunen^{1,2,72}

Uterine leiomyomata (UL) are the most common tumours of the female genital tract and the primary cause of surgical removal of the uterus. Genetic factors contribute to UL susceptibility. To add understanding to the heritable genetic risk factors, we conduct a genome-wide association study (GWAS) of UL in up to 426,558 European women from FinnGen and a previous UL meta-GWAS. In addition to the 50 known UL loci, we identify 22 loci that have not been associated with UL in prior studies. UL-associated loci harbour genes enriched for development, growth, and cellular senescence. Of particular interest are the smooth muscle cell differentiation and proliferation-regulating genes functioning on the myocardin-cyclin dependent kinase inhibitor 1 A pathway. Our results further suggest that genetic predisposition to increased fat-free mass may be causally related to higher UL risk, underscoring the involvement of altered muscle tissue biology in UL pathophysiology. Overall, our findings add to the understanding of the genetic pathways underlying UL, which may aid in developing novel therapeutics.

Uterine leiomyomata (UL) are the most common benign tumours of the female genital tract, with an estimated lifetime incidence of up to 70%¹ and the primary cause of hysterectomy. Female sex hormones stimulate UL growth and, thus, UL are almost exclusively found in females of reproductive age. UL are present in single or multiple numbers, with sizes ranging from millimetres to 20 cm or more in diameter², and they are composed mostly of smooth muscle cells (SMC) and fibroblasts with a profound component of extracellular matrix (ECM). In 25–50% of women with ULs, the enlarged and deformed uterus causes symptoms that reduce the quality of life, such as heavy or prolonged menstrual bleeding resulting in anaemia, reduced fertility and pregnancy complications³.

Until recently, the focus in the genetics of UL has been on somatic rearrangements, and key driver variations, for example, in *MED12* and *HMG2* have been reported⁴. Familial aggregation, the disparity in prevalence between different ethnic groups, and high heritability estimates obtained in twin studies (h^2 up to 69%) suggest, however, that heritable genetic factors modulate UL risk^{5–8}. To date, 11 GWASs on UL have been conducted in populations of European, Japanese, and African ancestries^{9–19}. In a recent UL meta-GWAS, the SNP-based heritability of UL was estimated to be 2.8%¹², suggesting that there may be other genetic variants contributing to UL susceptibility that are yet to be discovered.

Significant GWAS findings provide opportunities for testing causal inferences between UL and traits associated with UL. For instance,

¹Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland. ²Biocenter Oulu, Oulu, Finland. ³Oxford Endometriosis CaRe Centre, Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK. ⁴Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. ⁵Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland. ⁶PEDEGO Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland. ⁷Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland. ⁷²These authors contributed equally: Outi Uimari, Johannes Kettunen. *A list of authors and their affiliations appears at the end of the paper. ✉e-mail: eeva.sliz@oulu.fi

the causal relationship between UL and excessive menstrual bleeding has been demonstrated using the Mendelian randomisation method¹². The causal inferences between UL and metabolic risk factors, such as blood lipid levels or body mass index (BMI), however, have not been extensively studied even if previous cross-sectional studies indicate that those are associated with UL risk²⁰.

In this work, we conducted two sets of meta-analyses with data from FinnGen and a previously published UL meta-GWAS¹² in order to add understanding to the UL-related heritable genetic risk factors. We further utilised the GWAS results to estimate genetic correlations and causal relationships between UL and metabolic and anthropometric traits. Our findings provide a different perspective on UL pathobiology and suggest an involvement of fat-free mass rather than fat mass in the underlying causal pathway.

Results

22 uterine leiomyomata-associated loci that have not been described in prior studies

'META-1' comprised data from FinnGen and the previous UL meta-GWAS¹² with up to 53,534 cases and 373,024 female controls, and the analysis was restricted to publicly available 10,000 variants from the previous study¹². 'META-2' was conducted with data from up to 38,466 cases and 329,437 controls from FinnGen and the genome-wide summary statistics from the same study by ref.¹² excluding 23andMe data due to the data usage policy. The study setting is illustrated in Fig. 1.

In META-1, we identified 63 genomic regions located more than 1 Mb apart with at least one variant associating with UL at $p < 5 \times 10^{-8}$ (Fig. 2, Table S1, and Supplementary Data 1, 2); of these, 16 had not been reported in association with UL in prior UL GWASs (Table 1) while the remaining 47 were in the proximity of known UL risk loci. In META-2, we identified 61 genomic regions, out of which six had not been associated with UL risk in prior GWASs or in META-1 (Fig. 2, Table 1, Table S2, and Supplementary Data 3). However, the association at 10q24.32-10q25.1 likely spans a region larger than the ± 1 Mb locus definition overlapping with a previously reported UL association near STN1 subunit of CST complex (*STN1*) and STE20-like kinase (*SLK*)¹². This expanded association signal appears to be driven by variants enriched in the Finnish population (Finnish enrichment 46x-198x calculated as a ratio of the Finnish allele frequency and the non-Finnish-non-Estonian European allele frequency; Table 1). Regional association plots of the loci that have not been associated with UL risk in prior studies are presented in Figs. S1–S18, and the regional plot of the large signal on chr10 is presented in Fig. S19. Genomic inflation factor of 1.105 suggested minor inflation in the test statistics that was most notably accounted for by a polygenic signal, with the intercept being close to one²¹ (1.0066; Fig. S20). There was very little or no heterogeneity between the results obtained in FinnGen and the previous study¹² (Table 1 and Fig. S21). We estimated LD score (LDSC) regression-derived SNP-based heritability to be 0.105 (standard error [SE] = 0.011) on the liability scale, which corresponds to an -7.7 percentage point increase compared with the LDSC-based estimate obtained in the previous study¹². The SNP-based heritability estimate obtained additionally using SumHer²² was 0.034 (SE = 0.003).

Characterisation of the genome-wide results of META-2 suggested that the key UL-associated variants were mostly intronic (Fig. 3a and Supplementary Data 1). We also found enrichment in variants located on 3' untranslated regions, 5' untranslated regions, and upstream sequences, whereas the proportions of intergenic and non-coding RNA variants were lower than expected by chance (Fig. 3a).

In the conditional association tests conducted using genome-wide results from META-2, we identified secondary signals in altogether 14 loci (Table S2). Multiple signals were detected in some of the loci, including the well-known UL-risk locus on chr13 near 'forkhead box O1' (*FOXO1*), in which we observed four secondary signals in addition to the original association. The lead variants of these secondary signals

were either intronic (rs7986407, rs9548898 and rs6563799) or intergenic (rs9576914). Of the UL risk loci that had not been identified in prior studies, we detected a secondary signal in chr2 near 'myocardin-induced smooth muscle cell lncRNA, an inducer of differentiation' (*MYOSLID*) where an intronic variant (rs7584910) reached genome-wide significance ($p = 4.75 \times 10^{-8}$) after conditioning the association to the original lead variant (Table S2).

The results of fine-mapping on 146 association signals, including all UL associations in META-1 and META-2 as well as the independent associations observed in the conditional tests, suggested that 6 signals (near Meis homeobox 1 [*MEIS1*], inositol 1,4,5-trisphosphate receptor type 1 [*ITPR1*], spectrin repeat containing nuclear envelope protein 1 [*SYNE1*], forkhead box O1 [*FOXO1*], tumour protein p53 [*TP53*] and minichromosome maintenance 8 homologous recombination repair factor [*MCM8*]) had a single variant in the 99% credible set concordantly in both META-1 and META-2 (Tables S3, S4). Of these, the missense variant rs16991615 in *MCM8*, the 3'UTR variant rs78378222 in *TP53*, and the intron variant rs117245733 in LINC00598 near *FOXO1* have been reported previously¹². The remaining variants, i.e. rs17631680 near *MEIS1*, rs3804984 near *ITPR1* and rs58415480 near *SYNE1* are intergenic or intronic variants with no strong evidence of regulatory consequences according to RegulomeDB²³ and, thus, the association-driving mechanism remains unclear. In addition, 6 secondary signals were found to have a single variant in the 99% credible set (Table S5), all of which were intronic/intergenic.

Description of the key loci

Previous GWAS findings have indicated that genetic factors altering pathways involved in oestrogen signalling, Wnt signalling, transforming growth factor (TGF)- β signalling, and cell cycle progression are associated with UL risk¹⁰⁻¹⁹. The loci identified in this study further underscore the involvement of pathways regulating SMC proliferation in the modulation of UL risk. Many of these pathways are interrelated: for example, both oestrogen and progesterone increase the secretion of Wnt ligands from myometrial or leiomyoma SMC, which promotes cell proliferation and tumorigenesis via activation of β -catenin²⁴. Steroid hormones also influence the production of ECM via signalling through the TGF- β family of ligands and receptors that are highly expressed in multiple fibrotic conditions and contribute to the fibrotic phenotype seen in UL²⁵. We identified multiple loci with potential candidate genes functioning in one or more of these pathways, and, in the following, we describe some of our key findings with a focus on loci involved in the regulation of SMC proliferation.

A central finding is an association at 17p12 harbouring myocardin (*MYOCD*; Tables S1,S2). Myocardin is a transcription factor expressed in smooth muscle tissues, including most prominently arteries and colon, but also the uterus (Fig. S22), and it is required for SMC differentiation²⁶. The expression of myocardin has been shown to be downregulated in UL tissue compared with normal myometrium²⁷. Also, it has been proposed that the loss of myocardin function may be a key factor in driving SMC proliferation in UL²⁷; however, prior to our findings, only one study⁹ has reported GWAS association implicating myocardin. The lead variants near *MYOCD* are intergenic variants with no strong evidence of altered regulatory consequences (Table S6), and, thus, a possible association-driving mechanism remains inconclusive. We identified another myocardin-related UL risk association at 2q33.3 near *MYOSLID*, a transcriptional target of myocardin²⁸ (Fig. S3)—this locus has not been reported in prior studies. The association lead variant (rs10804157) is a regulatory variant (Table S7) altering the binding of multiple transcription factors (Table S8), including Fos proto-oncogene (FOS) that has been shown to be downregulated in UL²⁹. To add yet another example of a myocardin-related UL risk locus, a well-established association at 22q13.1^{10,12,15,16} locates near 'myocardin-related transcription factor A' (*MRTFA*; also known as *MKLI*), a gene interacting with myocardin.




Fig. 1 | Study setting. The flow diagram illustrates the data usage and analytical steps of our study. We conducted a GWAS of uterine leiomyomata (UL) in 18,060 cases and 150,519 female controls from the FinnGen project. Subsequently, we meta-analysed the FinnGen-based results with summary statistics from a previous UL meta-GWAS¹². META-1 included 53,534 cases and 373,024 female controls and was restricted to the top 10,000 variants from the previous study¹². META-2 was conducted genome-wide in 38,466 cases and 329,437 female controls, excluding 23andMe data due to the data usage policy. Downstream analyses assessing

functional annotations, gene-based associations, pathway enrichment, conditional association tests, fine-mapping, and genetic correlations were conducted using genome-wide summary statistics from META-2. In addition, fine-mapping was also conducted for the results of META-1. In Mendelian randomisation analyses evaluating causal inferences between UL and other, mostly UKBB-based traits, we extracted instruments for UL from the FinnGen-based summary statistics to avoid possible bias from overlapping UKBB samples.




Fig. 2 | A combined Manhattan plot of uterine leiomyomata (UL) associations in two sets of meta-analyses. We conducted UL GWAS in FinnGen and, subsequently, two sets of meta-analyses with data from a previously published UL meta-analysis¹². META-1 (top) was limited to the top 10,000 most significant variants from the previous study¹², and included up to 53,534 UL cases and 373,024 female controls whereas META-2 (bottom) was conducted genome-wide in 38,466 UL

cases and 329,437 female controls. The purple colour denotes UL risk loci identified in META-1 that have not been described in prior studies, and the pink color indicates loci identified in META-2 that were not associated previously with UL risk in prior GWASs or META-1. Black and grey colours indicate odd and even chromosome numbers, respectively. The red dashed lines correspond to the threshold for genome-wide significance ($p < 5 \times 10^{-8}$).

Others have suggested that loss of myocardin function may account for the differentiation defects of human leiomyosarcoma cells during malignant transformation³⁰; downregulation of myocardin resulted in lower expression of cyclin-dependent kinase inhibitor 1A (*CDKN1A*; also known as p21), a mediator of cell cycle G1 phase arrest, which facilitated cell cycle progression. The lead variants of the UL association at 6p21.2⁹ near *CDKN1A* locate in an intergenic region with possible regulatory consequences (Table S9). Previous evidence suggests that *CDKN1A* is among the genes, the expression of which correlates with UL size³¹. The UL association at 20q13.31⁹ harbours RNA binding motif protein 38 (*RBM38*; Fig. S14) that binds to and regulates the stability of *CDKN1A* transcripts³². In this locus, the UL risk-increasing rs13039273-C is associated with lower *RBM38* expression in the ovary ($p = 8.7 \times 10^{-6}$; Fig. S23; nominal significance in the uterus, $p = 2.2 \times 10^{-3}$). Interestingly, oestrogen receptor (ER) α has been shown to inhibit the expression of myocardin²⁷, suggesting that the ability of myocardin-*CDKN1A*-signalling to inhibit cell cycle progression may be

impaired in tissues enriched with ER α . Taking together our findings and previous evidence, it seems highly probable that downregulation of myocardin-*CDKN1A* signalling increases the risk of UL.

Enrichment for genes regulating development, growth, and cellular senescence

In a gene-based association test, we identified 97 genes associated with UL risk (Fig. 3b and Supplementary Data 1) that were enriched for 50 curated gene sets and/or Gene Ontology (GO) terms (Fig. 3c and Table S10). These included multiple terms related to developmental processes such as, most notably, gonad development ('regulation of male gonad development', false discovery rate (FDR)-corrected p value ($p_{\text{FDR}} = 1.78 \times 10^{-7}$; 'regulation of gonad development', $p_{\text{FDR}} = 0.0017$; 'positive regulation of gonad development', $p_{\text{FDR}} = 0.0065$; 'negative regulation of gonad development', $p_{\text{FDR}} = 0.042$) but also others, including the development of kidney, respiratory system, biomineral tissue, and adrenal gland ('kidney mesenchyme development',

Table 1 | Overview of 22 loci that have not been reported in association with UL in prior studies

Locus	Chr:Pos (hg38)	Nearest gene(s)	Candidate gene(s)	rsID	EA	EAF	OR (95% CI)	P value	HetPVal	INFO _{FinnGen}	FIN enr.
META-1											
1q43	1:241860596	EXO1	EXO1, FH	rs4149909	G	0.03	1.13 (1.08-1.18)	1.16E-08	0.265	0.996	1.03
1q44	1:244151650	ZBTB18, Ctorf100	ZBTB18, AKT3	rs2183478	G	0.18	1.07 (1.05-1.09)	1.75E-11	0.774	0.969	1.57
2q33.3	2:207259660	MYOSLID, KLF7	MYOSLID	rs10804157	C	0.44	1.04 (1.03-1.05)	1.04E-08	0.143	0.994	0.87
3q27.2	3:185807411	IGF2BP2	IGF2BP2	rs13060777	G	0.26	1.05 (1.04-1.07)	1.14E-11	0.595	0.999	1.10
4q23	4:99031559	METAP1	EIF4E, ADH5	rs1037475	G	0.57	1.04 (1.03-1.05)	8.38E-09	0.707	1.000	0.95
5q31.1	5:133099880	HSPA4	HSPA4	rs4367292	T	0.27	0.96 (0.94-0.97)	2.49E-08	0.882	0.997	1.15
6q21	6:109054915	SESN1	SESN1	rs11153158	C	0.13	0.93 (0.92-0.95)	1.05E-10	0.243	0.996	1.19
7p14.3	7:33008785	FKBP9, NT5C3A	NT5C3A, BBS9	rs4723230	T	0.80	1.05 (1.03-1.07)	4.68E-08	0.946	0.998	1.03
7q31.31	7:121132432	CPED1	WNT7B	rs12706314	A	0.53	1.04 (1.03-1.06)	2.69E-10	0.777	0.998	0.89
7q32.3	7:130935964	LINC-PINT	LINC-PINT	rs35908158	C	0.08	1.08 (1.05-1.10)	1.60E-08	0.883	0.998	1.41
10p12.31	10:21517903	SKIDA1	DNAJC1	rs946711	C	0.33	1.05 (1.03-1.06)	2.96E-10	0.460	0.995	0.96
10q23.31	10:88331783	RNLS	RNLS	rs14256619	T	0.45	1.04 (1.03-1.06)	4.92E-09	0.653	0.998	1.09
11q23.2	11:112703765	ENSG00000285769	ENSG00000285769	rs10891420	C	0.42	1.05 (1.03-1.06)	1.38E-10	0.019	0.995	1.16
20q13.31	20:57441016	CTCF	RBM38, BMP7	rs13039273	C	0.46	1.04 (1.03-1.06)	3.08E-09	0.874	0.995	1.22
21q22.12	21:35072824	RUNX1	RUNX1	rs2834747	G	0.30	0.96 (0.94-0.97)	1.44E-08	0.711	0.997	1.17
22q12.3	22:36287509	MYH9, APOL1	MYH9	rs9610482	T	0.19	1.06 (1.04-1.08)	7.89E-11	0.354	0.994	0.94
META-2											
10q22.3	10:76884502	KCNMA1	KCNMA1	rs2082415	T	0.52 ^f	1.05 (1.03-1.06)	2.80E-08	0.460	0.949	1.11
10q24.32 ^a	10:101726828	FGF8	SLK	rs189195982	T	0.03 ^f	1.26 (1.17-1.36)	2.78E-10	0.285	0.994	198.19
10q24.32 ^a	10:102788270	WBPTL	SLK	rs75731980	T	0.06 ^f	1.23 (1.17-1.30)	2.42E-16	0.801	0.992	46.07
10q25.1 ^a	10:105587387	SORCS3	SLK	rs17119191	T	0.97 ^f	0.76 (0.70-0.82)	5.81E-13	0.314	0.977	49.89
10q25.1 ^a	10:106822067	SORCS1	SLK	rs1336619	T	0.03 ^f	1.25 (1.17-1.34)	3.48E-10	0.127	0.999	7.47
12q15	12:68692314	NUPI07	MDM2	rs142808358	T	0.03 ^f	0.87 (0.83-0.91)	5.45E-09	0.958	0.987	0.87

^fNearest gene(s) reports the gene closest to the association lead variant.

^aCandidate gene(s) indicates the biologically most relevant gene within a 1 Mb window around the association lead variant.

Chr chromosome, Pos position (build 38), EA effect allele, EAF effect allele frequency, OR odds ratio, CI confidence interval, P p value, HetPVal p value for heterogeneity, INFO_{FinnGen} imputation info in FinnGen, FIN enr FinnGen enrichment (calculated as FIN AF/NFEE AF in the Genome Aggregation Database (gnomAD), where FIN AF is the Finnish allele frequency and NFEE AF is the non-Finnish non-Estonian European allele frequency).

^bThe locus spans a genomic region larger than ±1 Mb.

^cFinnGen-based effect allele frequency (allele frequencies were not available for the genome-wide summary statistics of the previous study¹⁷).

The table reports distinct loci (more than 1 Mb apart) that contain at least one variant identified to be associated with UL at $p < 5 \times 10^{-8}$ and that have not been reported in association with UL in prior studies. META-1 is a meta-analysis of 53,534 UL cases and 373,024 female controls from FinnGen limited to the top 10,000 variants of a previously published meta-GWAS of UL¹⁹, and META-2 is a meta-analysis of 38,466 UL cases and 329,473 female controls from FinnGen and the genome-wide results of the same meta-GWAS² excluding 23andMe data. All significant loci are listed in Tables S1, S2.




Fig. 3 | Variant summary and gene set-based results using genome-wide summary statistics from META-2. a The proportions of ‘independent genome-wide significant variants’ and ‘variants in LD with independent significant variants’ having corresponding functional annotation. Bars are coloured according to $-\log_2(\text{enrichment})$ relative to all variants in the reference panel. *P* values are obtained using Fisher’s exact test (two-sided). **b** A Manhattan plot of the gene-based test computed by MAGMA⁵¹. The input variants were mapped to 19,920

protein-coding genes and, thus, significance was considered at $p < 2.51 \times 10^{-6}$ (0.05/19,920). Purple and pink colours indicate odd and even chromosome numbers, respectively. Thirty-seven gene symbols are omitted. **c** MAGMA⁵¹ gene-set enrichment analysis was performed for curated gene sets and GO terms available at MsigDB⁵². The plot shows the results for significantly enriched pathways ($p_{FDR} < 0.05$). All data plotted in Fig. 3a–c were produced using FUMA⁴⁹.

$p_{FDR} = 0.0063$; ‘metanephric mesenchyme development’, $p_{FDR} = 0.0065$; ‘cell proliferation involved in metanephros development’, $p_{FDR} = 0.028$; ‘respiratory system development’, $p_{FDR} = 0.0063$; ‘diaphragm development’, $p_{FDR} = 0.0097$; ‘regulation of biomineral tissue development’, $p_{FDR} = 0.031$; ‘adrenal gland development’, $p_{FDR} = 0.049$). UL-associated genes were also enriched for the regulation of cell cycle and senescence (‘regulation of cell cycle’, $p_{FDR} = 0.028$; ‘positive regulation of cell cycle’, $p_{FDR} = 0.034$; ‘cell cycle’, $p_{FDR} = 0.048$; ‘cellular senescence’, $p_{FDR} = 0.031$; ‘stress-induced premature senescence’, $p_{FDR} = 0.049$). Enrichment for a curated gene set ‘RUNX3 regulates CDKN1A transcription’ ($p_{FDR} = 0.049$) provided further evidence that *CDKN1A*-related signalling may play a key role in UL. In addition, four of the terms, namely ‘positive regulation of heart growth’ ($p_{FDR} = 0.0052$), ‘positive regulation of organ growth’ ($p_{FDR} = 0.028$), ‘regulation of heart growth’ ($p_{FDR} = 0.041$), and ‘organ growth’ ($p_{FDR} = 0.049$) indicated enrichment for genes that function in processes activating growth rate and increasing the size or mass of organs and heart in particular.

Gene expression colocalization and mediation effects

Expectedly, the strongest positive relationships between the expression of UL-associated genes and disease-gene associations were seen in the uterus and cervix (Fig. S24). We found evidence of the colocalization of UL signals with gene expression of 16 genes in one or more of the four studied tissues (posterior probability (PP) for a shared

variant ≥ 0.8 ; Fig. 4a and Supplementary Data 1, 4). At 16q12.1, a well-known UL risk locus, the UL association signal colocalized with the expression of *HEATR3* in all studied tissues (PP_{cultured fibroblasts} = 0.92; PP_{skeletal muscle} = 0.90; PP_{uterus} = 0.93; PP_{whole blood} = 0.95; Fig. 4b–e). Of the loci that had not been described in association with UL in prior studies, the association signal at 5q31.1 colocalized with the expression of heat shock protein family A (Hsp70) member 4 (*HSPA4*) in cultured fibroblasts (PP = 0.98) and skeletal muscle (PP = 0.93; Fig. 4f, g). Previous studies have shown *HSPA4* to associate with ERα and thus to play a role in oestrogen signalling³³ as well as to enhance the angiogenesis ability of vessel endothelial cells in placenta accreta, a condition where the placenta grows too deeply in the uterine wall³⁴. Both oestrogen signalling³⁵ and angiogenic growth factor dysregulation³⁶ are also involved in UL, which makes *HSPA4* a highly plausible candidate to drive the UL association at 5q31.1. We further tested if the UL-risk associations are mediated by gene expression in the significant loci. The results of the mediation tests were mostly inconclusive, and we found no genome-wide significant mediation effects that would have passed the test for heterogeneity in dependent instruments (HEIDI; $p_{HEIDI} \geq 0.05$) (Supplementary Data 5–8). In our study, the previously reported result suggesting that the expression of *HEATR3* mediates UL risk association at 16q12.1¹¹ reached genome-wide significance in whole blood ($p = 1.49 \times 10^{-9}$), skeletal muscle ($p = 4.78 \times 10^{-9}$), and transformed fibroblasts ($p = 3.21 \times 10^{-8}$) but none of the mediation effects




Fig. 4 | Colocalizations between UL-GWAS signals and eQTL signals. We estimated approximate Bayes factor colocalizations of UL association signals from META-2 and gene expression in GTEx v8⁵² (cultured fibroblasts, skeletal muscle, uterus, and whole blood) using coloc.abf function from the coloc R library⁵⁴. Altogether 92 genes, including the genes closest to the association lead variant at each UL-associated locus and biologically plausible candidate genes, when

different from the closest genes, were included in the analysis (Table S2). The figure illustrates **a** all genes, the expression of which colocalizes with UL signal (posterior probability for a single causal variant [PP4] >0.8) in at least one of the studied tissues, as well as colocalization signals for *HEATR3* in **b** cultured fibroblasts, **c** skeletal muscle, **d** uterus, and **e** whole blood, and for *HSPA4* in **f** cultured fibroblasts, and **g** skeletal muscle.

passed the HEIDI test (respective p values: $p_{\text{HEIDI.whole.blood}} = 2.71 \times 10^{-27}$, $p_{\text{HEIDI.skeletal.muscle}} = 2.51 \times 10^{-25}$, $p_{\text{HEIDI.transformed.fibroblasts}} = 5.71 \times 10^{-10}$).

Genetic correlations with metabolic and anthropometric traits
We used LDSC software²¹ to evaluate the genetic correlations (r_g) of UL with 20 metabolic and anthropometric traits (Fig. 5a, Table S11,




Fig. 5 | Genetic correlations and causal relationships between uterine leiomyomata and metabolic and anthropometric traits. We estimated **a** genetic correlations (r_g) between uterine leiomyomata (UL) and 20 metabolic and anthropometric traits using UL-GWAS data from META-2 ($n = 367,903$) and summary statistics for other traits as provided by the MRC Integrative Epidemiology Unit (IEU) GWAS database (n ranges from 33,231 to 757,601; the trait-specific sample sizes are provided in Table S11). The analysis software was LDSC²¹. To dissect the causal relationships, we performed bi-directional two-sample Mendelian randomisation (MR) implemented in the TwoSampleMR R library^{60,63}; the plots (**b**, **c**) show the causal estimates obtained using the inverse variance-weighted (IVW) method. We further estimated **d** the multivariable effects of whole-body fat-free mass, whole-body fat mass, and estradiol level on UL risk using the same TwoSampleMR R library^{60,63}. In sensitivity analyses, we derived causal estimates using **e** MR Egger (as implemented in TwoSampleMR), **f** outlier-corrected MR-PRESSO⁴³,

and **g** MRMix⁴⁴ methods for the traits showing a significant IVW-based causal effect on UL. For all MR analyses, genetic instruments for UL were extracted from the GWAS completed in FinnGen ($n = 123,579$) and for other, mostly UKBB-based, traits from the MRC IEU GWAS database (n ranges from 33,231 to 757,601; Table S11) except for estradiol, for which the instruments were extracted from a study by ref.⁶¹ ($n = 206,927$). In all Mendelian randomisation analyses, LD pruning was completed using a European population reference, the threshold of $r^2 = 0.001$, and a clumping window of 10 kb. False discovery rate (FDR)-corrected⁶⁴ p values < 0.05 were considered significant in primary analyses (**a–c**). Multivariable MR and sensitivity analyses (**d–g**) were considered exploratory, and no multiple testing correction was applied. The error bars represent the corresponding 95% confidence intervals (CI). Numerical details are provided in Tables S12–S15, and scatter plots and the results of the leave-one-out analyses are shown in Figs. S25, 26 and S28–35, respectively.

and Supplementary Data 1). In line with previous observational studies reporting associations between cardiometabolic risk factors and UL risk^{20,37}, we found UL to show a positive genetic correlation with serum triglyceride level ($r_g = 0.161$, $p_{FDR} = 1.10 \times 10^{-7}$), waist circumference ($r_g = 0.101$, $p_{FDR} = 1.23 \times 10^{-4}$), diastolic blood pressure ($r_g = 0.098$, $p_{FDR} = 2.76 \times 10^{-4}$), waist-to-hip ratio ($r_g = 0.095$, $p_{FDR} = 0.020$), body mass index (BMI; $r_g = 0.091$, $p_{FDR} = 7.63 \times 10^{-4}$), systolic blood pressure ($r_g = 0.061$, $p_{FDR} = 0.020$), whole-body fat mass ($r_g = 0.057$, $p_{FDR} = 0.026$), and hip circumference ($r_g = 0.051$, $p_{FDR} = 0.048$), and negative genetic correlation with concentrations of high-density lipoprotein cholesterol (HDL-C; $r_g = -0.139$, $p_{FDR} = 1.48 \times 10^{-7}$) and apolipoprotein A-I (ApoA-I; $r_g = -0.110$, $p_{FDR} = 1.13 \times 10^{-4}$). Somewhat unexpectedly, we found UL to be closely genetically correlated with basal metabolic rate ($r_g = 0.084$, $p_{FDR} = 0.002$), whole-body water mass ($r_g = 0.083$, $p_{FDR} = 0.002$), and whole-body fat-free mass ($r_g = 0.083$, $p_{FDR} = 0.003$). Compatible with these findings, UL showed a negative genetic correlation with the impedance of whole-body ($r_g = -0.130$, $p_{FDR} = 1.04 \times 10^{-5}$) (i.e. a bioelectrical measure used for estimating body composition; higher muscle mass leads to lower impedance). Compared with whole-body fat mass, the genetic correlations of UL with these anthropometric traits indicating good physical health (i.e. basal metabolic rate, water mass, and fat-free mass) tended to be more robust in terms of both larger r_g values and smaller p values.

Causal evidence underscores the involvement of altered muscle tissue biology

To further evaluate the causal relations between UL and the same 20 metabolic and anthropometric traits, we applied bi-directional two-sample Mendelian randomisation. Regarding circulating lipids, we found higher HDL-C to be causally associated with a lower risk of UL (inverse variance-weighted [IVW] method-based odds ratio [OR] = 0.89 [0.82, 0.97], $p_{FDR} = 0.037$; Fig. 5b, Table S12, and Supplementary Data 1). There was no evidence of a causal relationship between UL and blood triglyceride level (Fig. 5b) even if, among the studied traits, triglycerides showed the most robust genetic correlation with UL in terms of both r_g and p value (Fig. 5a). Likewise, atherogenic cholesterol measures, total-C and low-density lipoprotein (LDL)-C, and apolipoprotein B (ApoB) concentration were not causally related to UL risk (Fig. 5b).

We found multiple causal associations between anthropometric traits and UL risk (Fig. 5b). Of the traits commonly linked with compromised health, waist circumference (OR = 1.19 [1.05, 1.35], $p_{FDR} = 0.033$) and BMI (OR = 1.13 [1.03–1.24], $p_{FDR} = 0.037$) were causally associated with UL risk. Compared with these, the causal associations between UL and traits implying good physical health were somewhat more robust (basal metabolic rate: OR = 1.24 [1.08, 1.43], $p_{FDR} = 0.020$; whole-body water mass: OR = 1.22 [1.06, 1.40], $p_{FDR} = 0.033$; whole-body fat-free mass: OR = 1.24 [1.08, 1.42], $p_{FDR} = 0.020$; impedance of whole body: OR = 0.79 [0.69, 0.91],

$p_{\text{FDR}} = 0.020$). When considering the null causal effect of whole-body fat mass on UL risk ($p_{\text{FDR}} = 0.712$), it seems apparent that the causal effect of BMI on UL arises from the increased lean body mass rather than fat mass.

Taken together, it seems that obesity-related cardiometabolic risk factors may not play a causal role in the pathophysiology of UL even if those are associated with UL risk on a population level^{20,37}. Our findings are in line with a previous report suggesting obesity to be causal for uterine endometrial cancer, but not for the other four studied gynaecologic diseases, including UL³⁸. Of note, the causal relationship between UL and diastolic blood pressure remained inconclusive as the causal estimate was significant in both directions (Fig. 5b, c and Supplementary Data 1).

UL are considered oestrogen-dependent, and UL have higher ER α expression compared with normal uterine myometria³⁵. ERs are expressed in a variety of tissues, including all musculoskeletal tissues³⁹. In females, muscle mass and strength are closely coupled with oestrogen status: girls begin to gain muscle mass after the onset of puberty⁴⁰, whereas in older age, during perimenopausal and postmenopausal periods, muscle strength declines considerably⁴¹. If oestrogen enhances muscle growth⁴², the observed causal relationship between fat-free mass and UL risk could arise secondary to high oestrogen contributing to muscle growth. Therefore, we further tested the multivariable effects of whole-body fat-free mass, whole-body fat mass, and estradiol on UL risk. The results of the multivariable model (Fig. 5d and Table S13) indicate that, among the three traits, only whole-body fat-free mass has a nominally significant causal effect on UL risk ($p = 0.018$) and, thus, support the original findings.

We note that the results of Mendelian randomisation should be interpreted with caution: although we did not observe horizontal pleiotropy (Table S12), the causal estimates were typically heterogenic (Table S12; scatter plots in Figs. S25, 26). Funnel plots did not suggest major asymmetry indicative of directional pleiotropy; however, minor asymmetry due to outliers was present for some exposures (Fig. S27). We further obtained outlier-corrected estimates using MR-PRESSO⁴³ (Table S14) and an outlier-robust MRMix method⁴⁴ (Table S15). The results were highly matching to the original findings (Fig. 5f, g), thus providing assurance of the validity of the evidence obtained in the primary analyses. Also, in the leave-one-out sensitivity analyses (Figs. S28–35), all causal estimates were consistently positive (higher fat-free mass was causally associated with a higher risk of UL; Fig. S34) or negative (higher impedance was causally associated with a lower risk of UL; Fig. S32) suggesting that there is no single variant driving the causal associations.

Strengths and limitations

Compared with the previous UL GWASs, our study had a larger sample size, which facilitated discoveries of multiple association signals at loci that had not been described in prior studies and also confirmed a high number of previously reported UL risk loci. Importantly, careful manual curation of the biological function of the genes in the UL-associated loci was highly beneficial in providing an understanding of UL-related biology. Due to the limitations in data availability, we needed to conduct two distinct meta-analyses to maximise the sample size in META-1 (including 23andMe but limited to the top 10,000 variants from the previous study¹²) and to obtain genome-wide results in META-2 (including genome-wide data from the previous study¹² but excluding 23andMe). Multiple analyses conducted downstream of the GWAS provided further insights into the key genetic pathways. We found only minimal evidence suggesting that the UL risk associations would be mediated by gene expression; it must be acknowledged, however, that the currently available gene expression data is limited in terms of the number of relevant tissue samples (the number of samples with genotype data is only 129 for the uterus in GTEx Analysis Release V8) and the low statistical power may interfere the discovery of significant

effects. Regarding the multivariable Mendelian randomisation, the genetic instruments for estradiol are weaker than the instruments for body composition measures, which may contribute to poor statistical power to detect a causal effect—it would be beneficial to reassess the multivariable effects once a larger estradiol GWAS, preferably conducted in females, will be available potentially providing stronger instruments for MR. Given that our work only includes computational approaches, further functional studies would be warranted to provide molecular evidence for our findings. Finally, the replication of our findings in other non-European ethnicities would be of high value.

Discussion

The numerous UL risk loci identified in the present study provide valuable insights into the architecture of heritable genetic risk factors in UL. Multiple aspects of our study, including the results of gene-based enrichment analyses and LDSC regression-derived genetic correlations, indicate altered muscle tissue biology in UL. Most notably, Mendelian randomisation-based evidence suggesting a causal relationship between genetic tendency to accumulate fat-free mass and UL risk provides an alternative perspective on UL-related pathophysiology. When considering the oestrogen-dependency of UL, it remains possible that the oestrogen-rich environment, due to sexual maturity, may trigger excess SMC growth resulting in UL in women who are genetically inclined to build up muscle.

Currently, the only essentially curative treatment for UL is hysterectomy, which underscores the high demand for the development of alternative effective therapies². The herein presented results provide several potential targets for translational research to develop pharmacologic interventions for UL. Therapies targeted at myocardin-CDKN1A signalling or, considering the causal evidence, other factors regulating muscle growth may hold the greatest potential.

Methods

Our research complies with all relevant ethical regulations. FinnGen participants provided written informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, older research cohorts, collected before the start of FinnGen (in August 2017), were collected based on study-specific written informed consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (Helsingin ja Uudenmaan Sairaanhoidopiiri, HUS) approved the FinnGen study protocol Nr HUS/990/2017. The FinnGen study is approved by Finnish Institute for Health and Welfare (Terveyden ja hyvinvoinnin laitos, THL), approval number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017–3, VRK/6909/2018-3, VRK/4415/2019-3 the Social Insurance Institution (Kansaneläkelaitos, KELA) KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, and Statistics Finland TK-53-1041-17. The Biobank Access Decisions for FinnGen samples and data utilised in FinnGen Data Freeze 5 include THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland I186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017 and Terveystalo Biobank STB 2018001.

Study populations

FinnGen (www.finnngen.fi/en) is a public-private partnership project launched in 2017 with an aim to improve human health through genetic research. The project utilises genome information from a

nationwide network of Finnish biobanks that are linked with digital health records from national hospital discharge (available from 1968), death (1969-), cancer (1953-) and medication reimbursement (1995-) registries using the unique national personal identification codes. Ultimately, the data resource will cover roughly 10% of the Finnish population. We studied data from 123,579 female participants (18,060 UL cases and 105,519 female controls) from FinnGen Preparatory Phase Data Freeze 5. UL cases were required to have an entry of ICD-10: D25, ICD-9: 218, or ICD-8: 21899, and participants who had no records of these entries were deemed as controls. The mean age at the diagnosis was 46.8 years.

FibroGENE is a consortium of conventional, population-based and direct-to-consumer cohorts that was assembled to replicate and identify UL risk variants. In the study by Gallagher et al., they studied data from 35,474 UL cases and 267,505 female controls, including participants from four population-based cohorts (Women's Genome Health Study, WGHS; Northern Finland Birth Cohort, NFBC; QIMR Berghofer Medical Research Institute, QIMR; the UK Biobank, UKBB) and one direct-to-consumer cohort (23andMe). Detailed descriptions of cohorts and sample selections are available in Supplementary Methods of the original publication¹².

Genotyping, imputation, and quality control

In FinnGen, genotyping of the samples was performed using Illumina and Affymetrix arrays (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA). Sample quality control (QC) was performed to exclude individuals with high genotype missingness (>5%), ambiguous gender, excess heterozygosity (± 4 SD) and non-Finnish ancestry. Regarding variant QC, all variants with low Hardy-Weinberg equilibrium (HWE) p value ($< 1e-6$), high missingness (>2%) and minor allele count (MAC) < 3 were excluded. Chip genotyped samples were pre-phased with Eagle 2.3.5 with the number of conditioning haplotypes set to 20,000. Genotype imputation was carried out by using the Finnish population-specific SISu v3 reference panel with Beagle 4.1 (version 08Jun17.d8b) as described in the following protocol: dx.doi.org/10.17504/protocols.io.nmndc5e. In post-imputation QC, variants with imputation INFO < 0.6 were excluded.

Genotyping and subsequent imputation and QC procedures conducted in the previous study have been described in detail elsewhere¹². Shortly, in four of the study populations, namely WGHS, NFBC, QIMR and 23andMe, genotyping was performed using Illumina or Affymetrix platforms, and individuals with a genotyping call rate < 0.98 were excluded from the study. Imputation was performed using the reference panel from the 1000 Genomes Project European data Phase 3. In variant QC, variants with call rates of $< 99\%$ or with deviation from HWE equilibrium ($p < 1 \times 10^{-6}$) were excluded. UKBB data QC and imputation were performed centrally and are described elsewhere⁴⁵. Additional QC filters were applied to exclude poorly imputed ($r^2 < 0.4$) and rare (minor allele frequency [MAF] $< 1\%$) variants¹².

Genome-wide associations

The UL GWAS in FinnGen was completed using the Scalable and Accurate Implementation of Generalised (SAIGE) software version 0.36.3.2⁴⁶. The association models were adjusted for age, the first ten genetic principal components, and genotyping batch, and only variants with a minimum allele count of five were included in the analysis.

Meta-analyses

Two sets of fixed-effect, inverse variance-weighted meta-analyses (implemented in METAL⁴⁷ V.2011-03-25) were performed: the results obtained in FinnGen were meta-analyzed with (1) the top 10,000 most significant variants associating with UL in a published GWAS¹² (META-1) and (2) the genome-wide summary statistics of the same study¹². Statistical significance was considered at the standard genome-wide significance level ($p < 5 \times 10^{-8}$). The genomic inflation factor was

estimated using an automated LD score (LDSC) regression pipeline⁴⁸ using the genome-wide results from META-2.

Characterisation of association signals

We used a web-based platform, FUMA⁴⁹ (accessed on 05/18/2022), to perform functional annotations of the GWAS results: we completed functional gene mapping and gene-based association and enrichment tests using the genome-wide UL associations from META-2 and pre-defined lead variants as reported in Table S2. FUMA identifies variants showing genome-wide significant association ($p < 5 \times 10^{-8}$) with the study trait and, among the significant variants, identifies variants in low LD ($r^2 < 0.6$) as 'independent significant variants' and further identifies variants in LD ($r^2 > 0.6$) with the 'independent significant variants'; ANNOVAR⁵⁰ annotations are performed for all these variants to obtain information on the functional consequences of the key variants. MAGMA⁵¹, also implemented in FUMA, was used to perform gene-based association testing and gene-set enrichment analyses: gene-based p values were computed for protein-coding genes by mapping variants to genes and subsequent enrichment analyses were performed for the significant genes using 4728 curated gene sets and 6166 GO terms as reported in MsigDB⁵².

To further identify the potential UL candidate gene(s) with biologically relevant functions, we annotated all genes within a 1Mb window from the association lead variant. We explored information provided by GenBank³² and UniProt⁵³ to determine the functions of the genes. To complement the information available in these databases, a broad literature search was performed to identify previous work published regarding the genes of interest.

We further tested the colocalization of UL association signals and gene expression in GTEx v8 (accessed on 05/19/2022). To do this, we used genome-wide UL associations from META-2 and gene expression data (significant variant-gene pairs) from four tissues: cultured fibroblasts, muscle (skeletal), uterus, and whole blood. Colocalizations were performed per gene for altogether 92 genes covering the gene closest to the association lead variant at each UL-associated locus and biologically plausible candidate genes if different from the closest genes (Table S2). Approximate Bayes Factor (ABF) analyses were completed using 'coloc.abf' from the 'coloc' R library (5.1.0.1)⁵⁴ with default priors (i.e., $p_1 = p_2 = 1 \times 10^{-4}$, $p_{12} = 1 \times 10^{-5}$). Colocalizations with posterior probability > 0.8 for a shared causal variant were considered significant. To test if altered gene expression mediates UL risk associations, we used a method proposed by ref. ⁵⁵ as implemented in Complex Traits Genetics Virtual Lab (CTG-VL; beta-0.4)⁵⁶; we performed these tests using genome-wide UL results from META-2 and tissue-specific gene expression data (GTEx, V7) for cultured fibroblasts, skeletal muscle, uterus, and whole blood. We further used RegulomeDB (2.0.3)²³ to discover regulatory elements overlapping with the intergenic variants in the genome-wide significant UL risk loci that had not been associated with UL risk in prior studies.

To assess if the UL-associated loci harbour secondary association signals, we performed conditional association tests using Genome-wide Complex Trait Analysis (GCTA) software (1.93.0 beta Linux)⁵⁷ and genome-wide summary statistics from META-2. Here, FinnGen was used as a reference sample to estimate linkage disequilibrium (LD) corrections. The associations were first conditioned on the most significant variant (i.e. the variant with the smallest p value) at each genome-wide significant locus, and conditioning was continued until no variant attained $p < 5 \times 10^{-8}$. Using GCTA, we also conditioned the associations on a nearly 6 Mb region on chromosome 10 to estimate if the association signal near *STN1* spans a genomic region larger than the ± 1 Mb locus definition.

To further characterise the loci, we fine-mapped each locus discovered in the two meta-analyses, including all independent association signals discovered in the conditional analyses. We first extracted the summary statistics of each locus, and then applied the FinnGen

fine-mapping pipeline (available at <https://github.com/FINNGEN/finemapping-pipeline>, accessed on 2/2/2022) with default parameters. In brief, the pipeline calculates linkage disequilibrium within the regions of interest with LDstore2⁵⁸ using FinnGen samples, generates 99% credible sets using the SUM of Single Effects (SuSiE)⁵⁹ and provides a summary of the results.

SNP-based heritability and genetic correlations

The SNP-based heritability (h^2_{SNP}) of UL was estimated using LDSC regression implemented in LDSC software (v1.0.1)²¹ and genome-wide summary statistics from META-2. A population prevalence of 0.30 (as in ref.¹²) and a sample prevalence of 0.11 were used to estimate h^2_{SNP} on the liability scale. In addition, SNP-based heritability was also estimated using SumHer²² software (ldak5.2.linux), genome-wide summary statistics from META-2, the pre-computed UK Biobank-based BLD-LDAK model (-tagfile bld.ldak.hapmap.gbr.tagging), and population and sample prevalences of 0.30 and 0.11 as above. The -check-sums option was set to 'NO', because only ~2% of the variants present in the tagfile were missing from the META-2 summary statistics. To use the same set of variants in both heritability estimations, insertions and deletions were excluded from these analyses, as SumHer analyses only single nucleotide variations.

We further applied LDSC to estimate genetic correlations (r_g) of UL with 20 metabolic and anthropometric traits extracted from the GWAS database provided by the MRC Integrative Epidemiology Unit (IEU) (<https://gwas.mrcieu.ac.uk/>). The 20 traits and their corresponding GWAS-IDs at the MRC IEU database were as follows: apolipoprotein A-I (ApoA-I; ieu-b-107), apolipoprotein B (ApoB; ieu-b-108), basal metabolic rate (ukb-b-16446), body fat percentage (ukb-b-8909), body mass index (BMI; ukb-b-19953), C-reactive protein (CRP; bjj-a-14), diastolic blood pressure (ieu-b-39), fasting blood glucose adjusted for BMI (ebi-a-GCST007858), high-density lipoprotein cholesterol (HDL-C; ieu-b-109), hip circumference (ukb-b-15590), an impedance of whole body (ukb-b-19921), low-density lipoprotein cholesterol (LDL-C; ieu-b-110), systolic blood pressure (ieu-b-38), total cholesterol (ieu-a-301), triglycerides (ieu-b-111), waist circumference (ukb-b-9405), waist-to-hip ratio (ieu-a-72), whole-body fat mass (ukb-b-19393), whole-body fat-free mass (ukb-b-13354) and whole-body water mass (ukb-b-14540).

Mendelian randomisation

To test for causal inferences between UL and the above-described 20 metabolic and anthropometric traits, we performed bi-directional two-sample Mendelian randomisation. These analyses were completed using 'TwoSampleMR' R library (0.5.6)⁶⁰ (<https://mrcieu.github.io/TwoSampleMR/>). To avoid possible bias from overlapping samples, we extracted genetic instruments for UL from the GWAS results obtained in FinnGen, and for other, mostly UKBB-based traits from the GWAS database provided by the MRC IEU and integrated them into TwoSampleMR. LD pruning was completed using European population reference, a threshold of $r^2 = 0.001$, and a clumping window of 10 kb, as set as default in 'clump_data' function; the numbers of SNPs available for the analyses are listed in Table S12. The inverse variance-weighted (IVW) method was considered the primary analysis. In sensitivity analyses, we derived causal estimates using MR Egger (implemented in TwoSampleMR), MR-PRESSO (L.O)⁴³, and MRMix (O.L.O)⁴⁴ methods for the traits showing FDR-significant causal effects on UL in the primary analysis. The sensitivity analyses were conducted using the same sets of instruments that were used in the primary IVW analysis using an identical LD pruning approach. The estimates obtained in the sensitivity analyses were required to be in a matching direction with the IVW estimates to conclude a reliable causal effect. Egger intercepts were evaluated to assess horizontal pleiotropy. Cochran's Q statistics were derived using 'mr_heterogeneity' function to test for heterogeneity. To screen for highly influential variants that could drive the association, for example, due to horizontal pleiotropy, we performed leave-one-

out analyses using 'mr_leaveoneout' function. We also estimated the multivariable effects of fat-free mass, fat mass, BMI, and estradiol level on UL risk using TwoSampleMR. LD pruning was conducted with the same settings as described above. We used data from FinnGen to extract variant associations with UL, from the MRC IEU GWAS database to extract variant associations with fat-free mass, fat mass, and BMI, and from a Study by ref.⁶¹ to extract variant associations with estradiol.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The individual-level data are available under restricted access for legal and ethical reasons. Formal approval for the researchers is required to access the data: please see https://www.finnngen.fi/en/access_results for more details. Access to FinnGen GWAS summary statistics can be applied through an online form at <https://elomake.helsinki.fi/lomakkeet/102575/lomake.html>. Access to individual-level data and genotype data is managed by the Finnish Biobank Cooperative at the Fingenious portal [<https://site.fingenious.fi/en/>]. The expected response timeframe for access requests to individual-level data is 1-2 months, and the planned account termination date is December 31, 2027. The results of META-1 (UL associations limited to the top 10,000 variants from the previous study) are provided in Supplementary Data 2 and the results limited to the top 10,000 variants from META-2 are provided in Supplementary Data 3. The genome-wide association data generated in this study (META-2) have been deposited in the NHGRI-EBI GWAS Catalogue database under accession code [GCST90239856](https://www.ebi.ac.uk/gwas/studies/GCST90239856). The summary-level data other than the genetic associations generated in this study are provided in the Supplementary Information. The genome-wide data from the previous UL-GWAS by Gallagher et al. used in this study are available in the NHGRI-EBI GWAS Catalogue database under accession code [GCST009158](https://www.ebi.ac.uk/gwas/studies/GCST009158). The genome-wide data of the 20 metabolic and anthropometric traits used in calculating genetic correlations and causal inferences are available at the MRC IEU GWAS database [<https://gwas.mrcieu.ac.uk/>] (the trait-specific data can be extracted using the trait IDs listed in Table S11).

References

- Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D. & Schectman, J. M. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. *Am. J. Obstet. Gynecol.* **188**, 100–107 (2003).
- Walker, C. L. & Stewart, E. A. Uterine fibroids: the elephant in the room. *Science* **308**, 1589–1592 (2005).
- Stewart, E. A. et al. Uterine fibroids. *Nat. Rev. Dis. Prim.* **2**, 16043 (2016).
- Mäkinen, N. et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. *Science* **334**, 252–255 (2011).
- Luoto, R. et al. Heritability and risk factors of uterine fibroids - The Finnish Twin Cohort Study. *Maturitas* **37**, 15–26 (2000).
- Wise, L. A. et al. African ancestry and genetic risk for uterine leiomyomata. *Am. J. Epidemiol.* **176**, 1159–1168 (2012).
- Van Voorhis, B. J., Romitti, P. A. & Jones, M. P. Family history as a risk factor for development of uterine leiomyomas. Results of a pilot study. *J. Reprod. Med.* **47**, 663–669 (2002).
- Snieder, H., Macgregor, A. J. & Spector, T. D. Genes control the cessation of a woman's reproductive life: A twin study of hysterectomy and age at menopause. *J. Clin. Endocrinol. Metab.* **83**, 1875–1880 (1998).
- Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. *Nat. Genet.* **53**, 1415–1424 (2021).

10. Cha, P. C. et al. A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. *Nat. Genet.* **43**, 447–451 (2011).
11. Edwards, T. L. et al. A trans-ethnic genome-wide association study of uterine fibroids. *Front. Genet.* **10**, 1–16 (2019).
12. Gallagher, C. S. et al. Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. *Nat. Commun.* **10**, 1–11 (2019).
13. Hellwege, J. N. et al. A multi-stage genome-wide association study of uterine fibroids in African Americans. *Hum. Genet.* **136**, 1363–1373 (2017).
14. Ishigaki, K. et al. Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. *Nat. Genet.* **52**, 669–679 (2020).
15. Masuda, T. et al. GWAS of five gynecologic diseases and cross-trait analysis in Japanese. *Eur. J. Hum. Genet.* **28**, 95–107 (2020).
16. Rafnar, T. et al. Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and hormone-related traits. *Nat. Commun.* **9**, 1–9 (2018).
17. Välimäki, N. et al. Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability. *Elife* **7**, 1–50 (2018).
18. Sakai, K. et al. Identification of a novel uterine leiomyoma GWAS locus in a Japanese population. *Sci. Rep.* **10**, 1–8 (2020).
19. Eggert, S. L. et al. Genome-wide linkage and association analyses implicate FASN in predisposition to uterine leiomyomata. *Am. J. Hum. Genet.* **91**, 621–628 (2012).
20. Uimari, O. et al. Uterine fibroids and cardiovascular risk. *Hum. Reprod.* **31**, 2689–2703 (2016).
21. Bulik-Sullivan, B. et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
22. Speed, D. & Balding, D. J. SumHer better estimates the SNP heritability of complex traits from summary statistics. *Nat. Genet.* **51**, 277–284 (2019).
23. Boyle, A. P. et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* **22**, 1790–1797 (2012).
24. Ono, M. et al. Paracrine activation of WNT/ β -catenin pathway in uterine leiomyoma stem cells promotes tumor growth. *Proc. Natl Acad. Sci. USA* **110**, 17053–17058 (2013).
25. Ciebiera, M. et al. Role of transforming growth factor β in uterine fibroid biology. *Int. J. Mol. Sci.* **18**, 1–16 (2017).
26. Chen, J., Kitchen, C. M., Streb, J. W. & Miano, J. M. Myocardin: a component of a molecular switch for smooth muscle differentiation. *J. Mol. Cell. Cardiol.* **34**, 1345–1356 (2002).
27. Liao, X. H. et al. ER α inhibited myocardin-induced differentiation in uterine fibroids. *Exp. Cell Res.* **350**, 73–82 (2017).
28. Zhao, J. et al. MYOSLID is a novel serum response factor-dependent long noncoding RNA that amplifies the vascular smooth muscle differentiation program. *Arterioscler. Thromb. Vasc. Biol.* **36**, 2088–2099 (2016).
29. Raimundo, N., Vanharanta, S., Aaltonen, L. A., Hovatta, I. & Suomalainen, A. Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. *Oncogene* **28**, 1261–1273 (2009).
30. Kimura, Y., Morita, T., Hayashi, K., Miki, T. & Sobue, K. Myocardin functions as an effective inducer of growth arrest and differentiation in human uterine leiomyosarcoma cells. *Cancer Res.* **70**, 501–511 (2010).
31. Markowski, D. N. et al. HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas. *Genes Chromosomes Cancer* **49**, 661–668 (2010).
32. Clark, K., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J. & Sayers, E. W. GenBank. *Nucleic Acids Res.* **44**, D67–D72 (2016).
33. Dhamad, A. E., Zhou, Z., Zhou, J. & Du, Y. Systematic proteomic identification of the heat shock proteins (Hsp) that interact with estrogen receptor alpha (ER α) and biochemical characterization of the ER α -Hsp70 interaction. *PLoS ONE* **11**, 1–19 (2016).
34. Li, S.-C. et al. HSPA4 is a biomarker of placenta accreta and enhances the angiogenesis ability of vessel endothelial cells. *Int. J. Mol. Sci.* **23**, 5682 (2022).
35. Bakas, P. et al. Estrogen receptor α and β in uterine fibroids: a basis for altered estrogen responsiveness. *Fertil. Steril.* **90**, 1878–1885 (2008).
36. Tal, R. & Segars, J. H. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. *Hum. Reprod. Update* **20**, 194–216 (2014).
37. Boynton-Jarrett, R., Rich-Edwards, J., Malspeis, S., Missmer, S. A. & Wright, R. A prospective study of hypertension and risk of uterine leiomyomata. *Am. J. Epidemiol.* **161**, 628–638 (2005).
38. Masuda, T. et al. A Mendelian randomization study identified obesity as a causal risk factor of uterine endometrial cancer in Japanese. *Cancer Sci.* **111**, 4646–4651 (2020).
39. Sipilä, S. & Poutamo, J. Muscle performance, sex hormones and training in peri-menopausal and post-menopausal women. *Scand. J. Med. Sci. Sport* **13**, 19–25 (2003).
40. Wood, C. L., Lane, L. C. & Cheetham, T. Puberty: normal physiology (brief overview). *Best. Pract. Res. Clin. Endocrinol. Metab.* **33**, 101265 (2019).
41. Chidi-Ogbolu, N. & Baar, K. Effect of estrogen on musculoskeletal performance and injury risk. *Front. Physiol.* **9**, 1834 (2019).
42. Velders, M. & Diel, P. How sex hormones promote skeletal muscle regeneration. *Sport. Med.* **43**, 1089–1100 (2013).
43. Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).
44. Qi, G. & Chatterjee, N. Mendelian randomization analysis using mixture models for robust and efficient estimation of causal effects. *Nat. Commun.* **10**, 1–10 (2019).
45. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
46. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).
47. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
48. Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
49. Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1–11 (2017).
50. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, 1–7 (2010).
51. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, 1–19 (2015).
52. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739–1740 (2011).
53. Bateman, A. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* **47**, D506–D515 (2019).
54. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).

55. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
56. Cuellar-Partida, G. et al. Complex-traits genetics virtual lab: a community-driven web platform for post-GWAS analyses. Preprint at *bioRxiv* <https://doi.org/10.1101/518027> (2019).
57. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
58. Benner, C. et al. Prospects of fine-mapping trait-associated genomic regions by using summary statistics from genome-wide association studies. *Am. J. Hum. Genet.* **101**, 539–551 (2017).
59. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser. B Stat. Methodol.* **82**, 1273–1300 (2020).
60. Hemani, G. et al. The MR-base platform supports systematic causal inference across the human phenome. *Elife* **7**, 1–29 (2018).
61. Ruth, K. S. et al. Using human genetics to understand the disease impacts of testosterone in men and women. *Nat. Med.* **26**, 252–258 (2020).
62. Lonsdale, J. et al. The genotype-tissue expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
63. Hemani, G., Tilling, K. & Smith, G. D. Orienting the causal relationship between imprecisely measured traits using genetic instruments. *PLoS Genet.* **13**, e1007081 (2017).
64. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. Ser. B* **57**, 289–300 (1995).

Acknowledgements

The work was supported through The Sigrid Juselius Foundation (J.K.) and funds from the Academy of Finland [grant numbers 297338 (J.K.), 307247 (J.K.) and 338229 (E.S.)], Novo Nordisk Foundation [grant number NNF17OC0026062] (J.K.), Orion Research Foundation sr (E.S.), and The Finnish Medical Association (O.U.). The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sàrl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech Inc). Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (<https://www.ppsshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx>), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaille/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are members of BBMRI.fi infrastructure (www.bbMRI.fi). This research has been conducted using data from UK Biobank, a major biomedical database, (<http://www.ukbiobank.ac.uk/>) under project ID 9637 (Gallagher et al., 201913). The Genotype-Tissue

Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH and NINDS.

Author contributions

O.U. conceptualised the study. E.S., N.R., K.T.Z., C.M.B. and J.K. contributed to the analysis plan. E.S., J.S.T. and N.R. analyzed data and generate results. E.S., J.S.T., N.R., K.T.Z. and O.U. interpreted the results. E.S. and O.U. wrote the original manuscript. FinnGen provided data for the study. J.K. supervised the study, obtained funding, and provided additional study resources. All authors contributed to revising the content of the manuscript and approved the final version.

Competing interests

K.T.Z.: Competing financial interests: Scientific collaborations (grant funding) with Bayer AG, Roche Diagnostics Inc, MDNA Life Sciences, and Evotec. Competing non-financial interests: Board memberships of the World Endometriosis Society, World Endometriosis Research Foundation, and research advisory committee member of Wellbeing of Women UK. CMB: Competing financial interests: Scientific collaborations (grant funding) with Bayer AG, Roche Diagnostics Inc, MDNA Life Sciences, and Evotec. Scientific board Myovant; IDDM Member ObsEva. Competing non-financial interests: Chair ESHRE Endometriosis Guideline Development Group. The remaining authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-023-35974-7>.

Correspondence and requests for materials should be addressed to Eeva Sliz.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

FinnGen

Aarno Palotie^{8,9,10}, Mark Daly^{8,9,10}, Bridget Riley-Gills¹¹, Howard Jacob¹¹, Dirk Paul¹², Athena Matakidou¹², Adam Platt¹², Heiko Runz¹³, Sally John¹³, George Okafo¹⁴, Nathan Lawless¹⁴, Heli Salminen-Mankonen¹⁴, Robert Plenge¹⁵, Joseph Maranville¹⁵, Mark McCarthy¹⁶, Margaret G. Ehm¹⁷, Kirsi Auro¹⁸, Simonne Longerich¹⁹, Caroline Fox¹⁹,

Anders Mälarstig²⁰, Katherine Klinger²¹, Clement Chatelain²¹, Matthias Gossel²¹, Karol Estrada²², Robert Graham²², Robert Yang²³, Chris O'Donnell²⁴, Tomi P. Mäkelä²⁵, Jaakko Kaprio⁸, Petri Virolainen²⁶, Antti Hakanen²⁶, Terhi Kilpi²⁷, Markus Perola²⁷, Jukka Partanen²⁸, Anne Pitkäranta²⁹, Taneli Raivio²⁹, Raisa Serpi³⁰, Tarja Laitinen³¹, Veli-Matti Kosma³², Jari Laukkanen³³, Marco Hautalahti³⁴, Outi Tuovila³⁵, Raimo Pakkanen³⁵, Jeffrey Waring¹¹, Bridget Riley-Gillis¹¹, Fedik Rahimov¹¹, Ioanna Tachmazidou¹², Chia-Yen Chen¹³, Zhihao Ding¹⁴, Marc Jung¹⁴, Shameek Biswas¹⁵, Rion Pendergrass¹⁶, David Pulford³⁶, Neha Raghavan¹⁹, Adriana Huertas-Vazquez¹⁹, Jae-Hoon Sul¹⁹, Xinli Hu²⁰, Åsa Hedman²⁰, Manuel Rivas²², Dawn Waterworth³⁷, Nicole Renaud²⁴, Ma'en Obeidat²⁴, Samuli Ripatti⁸, Johanna Schleutker²⁶, Mikko Arvas²⁸, Olli Carpén²⁹, Reetta Hinttala³⁰, Arto Mannermaa³², Katriina Aalto-Setälä³⁸, Mika Kähönen³¹, Johanna Mäkelä³⁴, Reetta Kälviäinen³⁹, Valtteri Julkunen³⁹, Hilikka Soininen³⁹, Anne Remes⁴⁰, Mikko Hiltunen⁴¹, Jukka Peltola⁴², Minna Raivio⁴³, Pentti Tienari⁴³, Juha Rinne⁴⁴, Roosa Kallionpää⁴⁴, Juulia Partanen⁴⁵, Ali Abbasi¹¹, Adam Ziemann¹¹, Nizar Smaoui¹¹, Anne Lehtonen¹¹, Susan Eaton¹³, Sanni Lahdenperä¹³, Natalie Bowers¹⁶, Edmond Teng¹⁶, Fanli Xu⁴⁶, Laura Addis⁴⁶, John Eicher⁴⁶, Qingqin S. Li⁴⁷, Karen He³⁷, Ekaterina Khramtsova³⁷, Martti Färkkilä⁴³, Jukka Koskela⁴³, Sampsa Pikkariainen⁴³, Airi Jussila⁴², Katri Kaukinen⁴², Timo Blomster⁴⁰, Mikko Kiviniemi³⁹, Markku Voutilainen⁴⁴, Tim Lu¹⁶, Linda McCarthy⁴⁶, Amy Hart³⁷, Meijian Guan³⁷, Jason Miller¹⁹, Kirsi Kalpala²⁰, Melissa Miller²⁰, Kari Eklund⁴³, Antti Palomäki⁴⁴, Pia Isomäki⁴², Laura Pirilä⁴⁴, Oili Kaipainen-Seppänen³⁹, Johanna Huhtakangas⁴⁰, Nina Mars⁸, Apinya Lertratanakul¹¹, Marla Hochfeld¹⁵, Jorge Esparza Gordillo⁴⁶, Fabiana Farias¹⁹, Nan Bing²⁰, Margit Pelkonen³⁹, Paula Kauppi⁴³, Hannu Kankaanranta^{48,49,50}, Terttu Harju⁴⁰, Riitta Lahesmaa⁴⁴, Glenda Lassi¹², Hubert Chen¹⁶, Joanna Betts⁴⁶, Rajashree Mishra⁴⁶, Majd Mouded⁵¹, Debby Ngo⁵¹, Teemu Niiranen⁵², Felix Vaura⁵², Veikko Salomaa⁵², Kaj Metsärinne⁴⁴, Jenni Aittokallio⁴⁴, Jussi Hernesniemi⁴², Daniel Gordin⁴³, Juha Sinisalo⁴³, Marja-Riitta Taskinen⁴³, Tiinamaija Tuomi⁴³, Timo Hiltunen⁴³, Amanda Elliott^{8,10,53}, Mary Pat Reeve⁸, Sanni Ruotsalainen⁸, Benjamin Challis¹², Audrey Chu⁴⁶, Dermot Reilly⁵⁴, Mike Mendelson⁵⁵, Jaakko Parkkinen²⁰, Tuomo Meretoja⁴³, Heikki Joensuu⁴³, Johanna Mattson⁴³, Eveliina Salminen⁴³, Annika Auranen⁴², Peeter Karihtala⁴⁰, Päivi Auvinen³⁹, Klaus Elenius⁴⁴, Esa Pitkänen⁸, Relja Popovic¹¹, Jennifer Schutzman¹⁶, Diptee Kulkarni⁴⁶, Alessandro Porello³⁷, Andrey Loboda¹⁹, Heli Lehtonen²⁰, Stefan McDonough²⁰, Sauli Vuoti⁵⁶, Kai Kaarniranta³⁹, Joni A. Turunen^{57,58}, Terhi Ollila⁴³, Hannu Uusitalo⁴², Juha Karjalainen⁸, Mengzhen Liu¹¹, Stephanie Loomis¹³, Erich Strauss¹⁶, Hao Chen¹⁶, Kaisa Tasanen⁴⁰, Laura Huilaja⁴⁰, Katariina Hannula-Jouppi⁴³, Teea Salmi⁴², Sirkku Peltonen⁴⁴, Leena Koulou⁴⁴, David Choy¹⁶, Ying Wu²⁰, Pirkko Pussinen⁴³, Aino Salminen⁴³, Tuula Salo⁴³, David Rice⁴³, Pekka Nieminen⁴³, Ulla Palotie⁴³, Maria Siponen³⁹, Liisa Suominen³⁹, Päivi Mäntylä³⁹, Ulvi Gursoy⁴⁴, Vuokko Anttonen⁴⁰, Kirsi Sipilä^{59,60}, Hannele Laivuori⁸, Venla Kurra⁴², Laura Kotaniemi-Talonen⁴², Oskari Heikinheimo⁴³, Ilkka Kalliala⁴³, Lauri Aaltonen⁴³, Varpu Jokimaa⁴⁴, Marja Väärämäki⁴⁰, Laure Morin-Papunen⁴⁰, Maarit Niinimäki⁴⁰, Terhi Piltonen⁴⁰, Katja Kivinen⁸, Elisabeth Widen⁸, Taru Tukiainen⁸, Niko Välimäki⁶¹, Eija Laakkonen⁶², Heidi Silven⁶³, Riikka Arffman⁶³, Susanna Savukoski⁶³, Triin Laisk⁶⁴, Natalia Pujol⁶⁴, Janet Kumar¹⁷, Iris Hovatta⁶¹, Erkki Isometsä⁴³, Hanna Ollila⁸, Jaana Suvisaari⁵², Thomas Damm Als⁶⁵, Antti Mäkitie⁶⁶, Argyro Bizaki-Vallaskangas⁴², Sanna Toppila-Salmi⁶¹, Tytti Willberg⁴⁴, Elmo Saarentaus⁸, Antti Aarnisalo⁴³, Elisa Rahikkala⁴⁰, Kristiina Aittomäki⁶⁷, Fredrik Åberg⁶⁸, Mitja Kurki^{8,53}, Aki Havulinna^{8,52}, Juha Mehtonen⁸, Priit Palta⁸, Shabbeer Hassan⁸, Pietro Della Briotta Parolo⁸, Wei Zhou⁵³, Mutaamba Maasha⁵³, Susanna Lemmelä⁸, Aoxing Liu⁸, Arto Lehisto⁸, Andrea Ganna⁸, Vincent Llorens⁸, Henrike Heyne⁸, Joel Rämö⁸, Rodos Rodosthenous⁸, Satu Strausz⁸, Tuula Palotie⁶⁹, Kimmo Palin⁶¹, Javier Garcia-Tabuenca⁷⁰, Harri Siirtola⁷⁰, Tuomo Kiiskinen⁸, Jiwoo Lee^{8,53}, Kristin Tsuo^{8,53}, Kati Kristiansson²⁷, Kati Hyvärinen⁷¹, Jarmo Ritari⁷¹, Katri Pylkäs⁶³, Minna Karjalainen⁶³, Tuomo Mantere³⁰, Eeva Kangasniemi³¹, Sami Heikkinen⁴¹, Nina Pitkänen²⁶, Samuel Lessard²¹, Clément Chatelain²¹, Perttu Terho²⁶, Tiina Wahlfors²⁷, Eero Punkka²⁹, Sanna Siltanen³¹, Teijo Kuopio³³, Anu Jalanko⁸, Huei-Yi Shen⁸, Risto Kajanne⁸, Mervi Aavikko⁸, Henna Palin³¹, Malla-Maria Linna²⁹, Masahiro Kanai⁵³, Zhili Zheng⁵³, L. Elisa Lahtela⁸, Mari Kaunisto⁸, Elina Kilpeläinen⁸, Timo P. Sipilä⁸, Oluwaseun Alexander Dada⁸, Awaisa Ghazal⁸, Anastasia Kytölä⁸, Rigbe Weldatsadik⁸, Kati Donner⁸, Anu Loukola²⁹, Päivi Laiho²⁷, Tuuli Sistonen²⁷, Essi Kaiharju²⁷, Markku Laukkanen²⁷, Elina Järvensivu²⁷, Sini Lähteenmäki²⁷, Lotta Männikkö²⁷, Regis Wong²⁷, Auli Toivola²⁷, Minna Brunfeldt²⁷, Hannele Mattsson²⁷, Sami Koskelainen²⁷, Tero Hiekkalinna²⁷, Teemu Paajanen²⁷, Kalle Pärn⁸, Mart Kals⁸, Shuang Luo⁸, Shanmukha Sampath Padmanabhuni⁸, Marianna Niemi⁷⁰, Javier Gracia-Tabuenca⁷⁰, Mika Helminen⁷⁰, Tiina Luukkaala⁷⁰, Iida Vähätalo⁷⁰, Jyrki Tammerluoto⁸, Sarah Smith³⁴, Tom Southerington³⁴ & Petri Lehto³⁴

⁸Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. ⁹Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹⁰Massachusetts General Hospital, Boston, MA, USA. ¹¹Abbvie, Chicago, IL, US. ¹²Astra Zeneca, Cambridge, United Kingdom. ¹³Biogen, Cambridge, MA, US. ¹⁴Boehringer Ingelheim, Ingelheim am Rhein, Rhein, Germany. ¹⁵Bristol Myers Squibb, New York, NY, US. ¹⁶Genentech, San Francisco, CA, US. ¹⁷GlaxoSmithKline, Collegeville, PA, US. ¹⁸GlaxoSmithKline, Espoo, Finland. ¹⁹Merck, Kenilworth, NJ, US. ²⁰Pfizer, New York, NY, US. ²¹Translational Sciences, Sanofi R&D, Framingham, MA, USA. ²²Maze Therapeutics, San Francisco, CA, US. ²³Janssen Biotech, Beerse, Belgium. ²⁴Novartis Institutes for BioMedical Research, Cambridge, MA, US. ²⁵HiLIFE, University of Helsinki, Finland, Finland. ²⁶Auria Biobank, University of Turku, Hospital District of Southwest Finland,

Turku, Finland. ²⁷THL Biobank, Finnish Institute for Health and Welfare (THL), Helsinki, Finland. ²⁸Finnish Red Cross Blood Service, Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland. ²⁹Helsinki Biobank, Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki, Finland. ³⁰Northern Finland Biobank Borealis, University of Oulu, Northern Ostrobothnia Hospital District, Oulu, Finland. ³¹Finnish Clinical Biobank Tampere, University of Tampere, Pirkanmaa Hospital District, Tampere, Finland. ³²Biobank of Eastern Finland, University of Eastern Finland, Northern Savo Hospital District, Kuopio, Finland. ³³Central Finland Biobank, University of Jyväskylä, Central Finland Health Care District, Jyväskylä, Finland. ³⁴FINBB - Finnish biobank cooperative, Turku, Finland. ³⁵Business Finland, Helsinki, Finland. ³⁶GlaxoSmithKline, Stevenage, United Kingdom. ³⁷Janssen Research & Development, LLC, Spring House, PA, US. ³⁸Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. ³⁹Northern Savo Hospital District, Kuopio, Finland. ⁴⁰Northern Ostrobothnia Hospital District, Oulu, Finland. ⁴¹University of Eastern Finland, Kuopio, Finland. ⁴²Pirkanmaa Hospital District, Tampere, Finland. ⁴³Hospital District of Helsinki and Uusimaa, Helsinki, Finland. ⁴⁴Hospital District of Southwest Finland, Turku, Finland. ⁴⁵Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland. ⁴⁶GlaxoSmithKline, Brentford, United Kingdom. ⁴⁷Janssen Research & Development, LLC, Titusville, NJ 08560, US. ⁴⁸University of Gothenburg, Gothenburg, Sweden. ⁴⁹Seinäjoki Central Hospital, Seinäjoki, Finland. ⁵⁰Tampere University, Tampere, Finland. ⁵¹Novartis, Basel, Switzerland. ⁵²Finnish Institute for Health and Welfare (THL), Helsinki, Finland. ⁵³Broad Institute, Cambridge, MA, US. ⁵⁴Janssen Research & Development, LLC, Boston, MA, US. ⁵⁵Novartis, Boston, MA, US. ⁵⁶Janssen-Cilag Oy, Espoo, Finland. ⁵⁷Helsinki University Hospital and University of Helsinki, Helsinki, Finland. ⁵⁸Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland. ⁵⁹Research Unit of Oral Health Sciences Faculty of Medicine, University of Oulu, Oulu, Finland. ⁶⁰Medical Research Center, Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. ⁶¹University of Helsinki, Helsinki, Finland. ⁶²University of Jyväskylä, Jyväskylä, Finland. ⁶³University of Oulu, Oulu, Finland. ⁶⁴Estonian biobank, Tartu, Estonia. ⁶⁵Aarhus University, Aarhus, Denmark. ⁶⁶Department of Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁶⁷Department of Medical Genetics, Helsinki University Central Hospital, Helsinki, Finland. ⁶⁸Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki University, Helsinki, Finland. ⁶⁹University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland. ⁷⁰University of Tampere, Tampere, Finland. ⁷¹Finnish Red Cross Blood Service, Helsinki, Finland.